Skip to main content


As antibiotic resistance in pathogenic microorganisms continues to be a world-wide health and safety concern, the demand for new and more advanced antibiotics has never been more pressing. The rate of antibiotic resistance among clinically relevant pathogens continues to increase while, at the same time, drug discovery, as it relates to antimicrobial compounds, has slowed to the point of being essentially stalled. As such, the discovery of novel antimicrobial compounds from previously unexploited sources could lead to the development of potential novel antimicrobial drugs that are in short supply. In this work, we have isolated a strain of Trichosporon beigelii which we found to produce multiple antimicrobial compounds. By testing crude extracts in disk diffusion assays against multiple drug resistant strains of bacteria, these compounds have shown signs of potential clinical viability and preliminary selectivity for pathogenic microorganisms such as Methicillin Resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae at concentrations of 1 mg/mL. These compounds have been further isolated and purified, following growth and production of the compounds in rich media, by using organic chemistry liquid-liquid extractions, analytical and preparative HPLC, and disk diffusion assays in an attempt to determine their molecular structures and usability. The further isolation and purification of these compounds could, potentially, yield compounds that could be developed as novel antibiotics.


This is a metadata-only record.



  • Subject
    • Biology

  • Institution
    • Dahlonega

  • Event location
    • Nesbitt 3110

  • Event date
    • 23 March 2018

  • Date submitted

    19 July 2022

  • Additional information
    • Acknowledgements:

      Paul Johnson